Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to ZNF696 (ENSG00000272172) is a non-protein-coding RNA transcribed from the strand opposite to the ZNF696 gene. Antisense transcripts such as this are broadly present in mammalian genomes, often overlapping the coding regions of sense genes. They are primarily thought to modulate the expression of their corresponding sense genes by altering chromatin structure, influencing transcript stability, or interfering with transcription and splicing[1][3][4]. While antisense transcription can contribute to gene regulation, particularly through epigenetic modification and RNA-based mechanisms, these molecules are not considered classic drug targets. Their potential functions in disease are linked primarily to their effects on the regulation of coding genes rather than direct pathological roles[1][3][4].
Regulatory effects via\n Modulating chromatin state (e.g. histone acetylation, methylation)\n Interfering with sense transcript production and stability\n Forming double stranded RNA duplexes (potentially leading to RNA interference pathways)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ZNF696 (ENSG00000272172).